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PATIENT-REPORTED FREQUENCY, AWARENESS AND PATIENT-PHYSICIAN 
COMMUNICATION OF HYPOGLYCAEMIA IN BELGIUM  
Mathieu C1, D'Hooge D2, Vandebrouck T2 
1UZ Leuven campus Gasthuisberg, Leuven, Belgium, 2Novo Nordisk Pharma, Brussels,  
Belgium  
OBJECTIVES: Hypoglycaemia, a common side effect of insulin therapy, can act as 
a barrier to optimal diabetes management and has a negative impact on 
patients’ quality of life. However, there are few data on the frequency of 
hypoglycaemic events outside clinical trials. METHODS: Type-1 (T1) and insulin-
treated type-2 (T2: basal only, T2BOT; basal-bolus, T2BB; and other regimen, T2O) 
diabetes patients > 15 years old were recruited via existing panels in Belgium to 
complete four questionnaires at weekly intervals. In addition to demographics, 
data were collected on the frequency of non-severe hypoglycaemic events 
(NSHE), hypoglycaemia awareness and reporting of hypoglycaemia to physicians 
with a 7-day recall period. NSHE was symptoms of hypoglycaemia, with or 
without blood glucose measurement (BGM), or low BGM without symptoms, 
which the patient could manage without assistance. RESULTS: In total, 412 
patients (44% T1, 56% T2) completed 1148 patient-weeks. Mean 
insulin-treatment duration was 11 years, mean HbA1c 7.7%. Mean NSHE per 
patient-week were 2.3 in T1 patients, 0.3 in T2BOT, 0.7 in T2BB and 0.8 in T2O 
patients. Nocturnal NSHE accounted for 19% of T1 events, and 13% (T2BOT), 23% 
(T2BB) and 27% (T2O) of T2 events. Impaired awareness or unawareness of 
hypoglycaemia was reported by 72% of T1, 67% of T2BOT, 66% of T2BB and 74% 
of T2O patients. Overall, 60% of T1 patients and 46% of T2 patients rarely/never 
discuss hypoglycaemia with their GP/specialist. In addition, 10% of T1 patients 
and 13% of T2 patients stated that GPs/specialists did not ask them about their 
hypoglycaemia in routine appointments. CONCLUSIONS: NSHE are a common 
occurrence amongst insulin-treated patients in Belgium. As many patients do 
not often report their hypoglycaemia to their GP/specialist, the real-world rates 
may be underestimated. Many patients also reported an impaired or 
unawareness of hypoglycaemia, which may increase the risk of hypoglycaemic 
events.  
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TRENDS IN PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF 
DIABETES IN THE UNITED STATES, 1999-2010  
Lu K, Yuan J 
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OBJECTIVES: To examine progress in treating and controlling diabetes among 
U.S adults aged 20 years and older from 1999-2010. METHODS: Cross-sectional 
study of National Health and Nutrition Examination Survey (NHANES) 1999-2010, 
representing the civilian, noninstitutionalized population of the U.S. Diabetes 
was defined as fasting plasma glucose of at least 126mg/dl, HbA1c of at least 
6.5%, self-reported use of antidiabetic medications or insulin, self-reported 
awareness of diabetes, or both. Glycemic control was defined as HbA1c less than 
7%. All survey periods were age-adjusted to the year 2000 US population. 
RESULTS: Prevalence of diabetes increased from 8.5% (95% CI, 7.1-9.9%) in 1999-
2000 to 11.1% (95% CI, 9.8-12.4%) in 2009-2010 (P<.001). Glycemic Control 
increased from 38.1% (95%CI, 24.5-51.7%) in 1999-2000 to 56.7% (95%CI, 48.1-
65.2%) in 2009-2010 (P=0.003), and HbA1c level among diabetics decreased from 
8.1% (95%CI, 7.4-8.9%) in 1999-2000 to 7.4 % (95%CI, 7.0-7.7%) in 2009-2010 
(P=0.02). Improved Glycemic Control reflected improvements in treatment 
(78.4%; 95%CI, 68.2-88.5%; vs. to 86.7% (95%CI, 82.4-91.0%) overtime (P=0.05), and 
proportion of patients who were treated and achieved glycemic control (38.1%; 
95%CI, 24.5-51.7%; vs. 56.7%; 95%CI, 48.1-65.2%) between 1999-2000 and 2009-
2010, across age, race, and sex groups, but was lower among individuals aged 20 
to 39 years versus 60 years or older (P=0.01), in Black vs white individuals 
(P=0.02), and in Hispanic versus white individuals (P=0.003). CONCLUSIONS: 
Diabetes was controlled in an estimated 56.7% of all patients with diabetes in 
NHANES 1999-2010, with most of the improvement between 1999-2000 and 2003-
2004. Glycemic control was significantly lower among younger than older adults, 
Black vs white, and Hispanic vs white individuals.  
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OBJECTIVES: To analyse the relationship between prevalence of diabetes and 
Body Mass Index (BMI) and the distribution of people with diabetes among 
different BMI categories in Chinese adults. METHODS: Systematic review was 
conducted in China National Knowledge Infrastructure (CNKI) from 2006 to 2012. 
“Diabetes” and “BMI” were used as keywords. Inclusion criteria were studies that 
reported diabetes prevalence according to BMI categories. Exclusion criteria were 
studies that population were not adults or sample sizes were less than 1000. 
Underweight, normal, overweight and obesity were defined using the 
recommended Chinese BMI cut-off points of <18.5, 18.5-24, 24-28, >=28. Non-
linear regression in STATA was used to analysis the relationship between 
prevalence of diabetes and BMIs. Prevalence of diabetes were adjusted from 
existing data which was conducted according to WHO’ BMI classification criteria 
(<18.5, 18.5-25, 25-30, >=30) to meet Chinese BMI criteria, based on two 
nationwide representative studies of Yang et al. and Chinese Center For Disease 
Control And Prevention (CDC). Numbers of people with diabetes among BMI 
categories were calculated based on Chinese population. Sensitivity analysis was 
conducted. RESULTS: Twenty-three articles were selected, 8 of them met the 
eligibility criteria. Prevalence of diabetes increased with BMI and exponential 
regression model fit best. Yang et al. reported the prevalence of diabetes were 
4.5%, 7.6%, 12.8%, 18.5% according to WHO’s definition of underweight, normal, 
overweight and obesity respectively. The prevalence of diabetes were estimated 
to be 4.50%, 7.26%, 11.53%, 15.95% after adjusting by Chinese definition. 
Therefore, Chinese adults with diabetes were estimated to be 4.35 million, 35.13 
million, 35.70 million and 19.36 million respectively. Sensitivity analysis showed 
the non-linear regression model was robust. CONCLUSIONS: Prevalence of 
diabetes increase exponentially with BMI. Approximately 55 million adults with 
diabetes are overweight and obesity in China. Body weight control should be a 
priority in the prevention and management of diabetes.  
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ANTIDEPRESSANT USE AND THE RISK OF INCIDENT DIABETES: A SYSTEMATIC 
REVIEW AND META-ANALYSIS  
Bhattacharjee S1, Bhattacharya R1, Kelley G1, Sambamoorthi U2 
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of 
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OBJECTIVES: To assess the risk of incident diabetes associated with 
antidepressant use among adults. METHODS: A systematic literature search was 
conducted to identify relevant studies in seven different electronic databases 
(PubMed, CINAHL, Cochrane Library, Dissertation Abstracts International/ 
Proquest, Web of Science, Scopus, PsycINFO) along with cross-referencing from 
selected studies. Two independent reviewers identified the final studies to be 
included in the meta-analysis based on the following criteria: 1) observational 
studies; 2) adults ≥ 18 years of age; 3) antidepressant utilization; 4) published and 
unpublished (dissertations and Master’s theses) studies; 5) English language 
studies only; 6) studies published from the inception of the respective databases 
to November 26, 2012; 7) minimum follow-up of 12 months from the start of 
antidepressant use. The primary outcome was incident diabetes. Random-effects 
models were used to determine the relationship between antidepressant use and 
incident diabetes. Incident diabetes was measured among individuals with no 
prior history of diabetes. Presence of diabetes was assessed by any of the 
following: self-report, physician diagnosis, ICD-9-CM code of 250.xx, fasting 
(>110mg/dl) and post-prandial (>140mg/dl) blood glucose measures, HbA1C value 
≥7%, new prescription of oral antidiabetic medications or insulin. Egger’s 
regression test and Trim and Fill tests were used to detect the presence of any 
potential publication bias. Sensitivity analysis was conducted using the leave-
one-out method. RESULTS: Eight studies met the inclusion criteria. Random-
effects models revealed that adults using antidepressants were more likely to 
develop diabetes compared to those not using antidepressants (Odds Ratio=1.50, 
95% CI-1.08-2.09; Hazards Ratio=1.20, 95% CI-1.08-1.34). Sensitivity analyses 
revealed fair robustness. Results from the Egger’s regression test and Trim and 
Fill method revealed no evidence of publication bias. CONCLUSIONS: Among 
adults, antidepressants are associated with the risk of developing incident 
diabetes. Further cause-and-effect studies are needed to confirm this 
association.  
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TREATMENT RELATED SEVERE HYPOGLYCAEMIA RISK IN DIABETES TYPE-1 
AND TYPE-2–A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES  
Paweska J1, Barszcz E1, Jakubczyk M2, Niewada M3, Czech M4 
1HealthQuest spolka z ograniczona odpowiedzialnoscia Sp. K., Warsaw, Poland, 2Institute of 
Econometrics, Warsaw School of Economics, Warsaw, Poland, 3Department of Experimental and 
Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland, 4Novo Nordisk Pharma 
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OBJECTIVES: Severe (requiring assistance from another individual) 
hypoglycaemic events (SHEs) are important from both clinical and economic 
perspective. The aim was to assess SHEs risk related to major drug groups in 
type 1 and 2 diabetes (T1, T2) in real-life settings. METHODS: We systematically 
reviewed Medline, EMBASE and Cochrane databases for recent (<10 years), large 
(n ≥100) observational studies for drugs associated with higher SHEs risk by 
available guidelines (IDF, ADA, EASD) – i.e. insulins and sulphonylureas. We 
extracted number of SH events and patients experiencing at least one, number of 
participants and time horizon. Using a random effects Poisson model within 
MCMC framework we estimated the annual SHEs rates whenever the 
heterogeneity and number of studies allowed a reasonably credible estimate. 
RESULTS: Search strategies yielded 5220 studies, 525 full texts were analysed, 
and 43 were finally enrolled: 15 regarding long-acting insulin analogues (LAA),  
13 – pumps, 21 – other insulins (OI), 9 – sulphonylureas. Full texts were rejected 
mostly due to: inappropriate SHE definition, patients using a mixture of 
treatments, no precise treatment definition. We obtained the following ranges 
for SHE rates in individual studies. For T1: LAA (n=13, 0.10-1.47), pumps (n=17, 0-
0.58), OI (n=12, 0.20-1.26). For T2: LAA (n=5, 0-0.98), OI (n=10, 0-0.59), OI + 
sulphonylureas (n=4, 0-0.59), OI + other OADs (n=8, 0-0.72), sulfonylureas (n=6, 0-
0.11). Pooled data suggest the following mean annual SHE rates (95%CI). For T1: 
LAA 0.54 (0.33-0.88), pumps 0.17 (0.11-0.25), OI 0.67 (0.36-1.26). For T2: OI 0.34 
(0.07-0.68), sulfonylureas 0.06 (0.02-0.15). CONCLUSIONS: SHEs risk differs for T1, 
T2 and available drugs. However SHEs frequency may not seem large, the fear of 
such an event, its danger and economic consequences may be an important 
issue in managing diabetes. Limited availability of studies and heterogeneity of 
data make it difficult to come up with precise rate estimation.  
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OBJECTIVES: To estimate the budget impact of saxagliptin/metformin XR fixed-
dose combination introduction as a treatment option for patients with type 2 
diabetes mellitus (T2DM), compared to the present situation, in Chile. METHODS: 
An MS Excel-based budget impact model assuming coverage for one million 
people. The time horizon was three years and the analysis perspective was the 
National health Insurance system in Chile (FONASA). Prevalence information 
was obtained from published literature. Pharmaceutical expenses of oral anti-
diabetic agents were analyzed excluding other medical costs. The cost of oral 
anti-diabetic agents was based upon list prices adjusted to co-payments, 
expressed in Chilean pesos 2012 (exchange rate 1US$ = 487.8 CH$). The market 
share of the different drugs was based upon QUALIDIAB Database, market 
studies and data provided by Bristol Myers Squibb. The budget impact is reported 
in terms of annual budget impact, per-member per-month (PMPM) and per-
patient per-month (PPPM). A Monte Carlo simulation (10,000 iterations) was done 
as part of the sensitivity analysis. RESULTS: The net budget impact estimated for 
the introduction of saxagliptin/metformin XR combined was $2,772,663 for the 
first year, $25,680,312 for the second year and $81,609,192 for the third year; the 
cumulative net budget impact was $110,062,166. PMPM was $0.23, $2.14 and $6.8 
for the first, second and third year respectively. PPPM was $9.2, $85.0 and $270.3 
each year, respectively. The cumulative impact in the total annual budget for 
oral anti-diabetic agents represented an increase of 1.6%. Monte Carlo simulation 
showed that cumulative budget impact varied from 1.1 to 1.8%. CONCLUSIONS: 
This study showed that the introduction of saxagliptin/metformin XR combined, 
as a treatment option for patients with T2DM, into the national health insurance 
system of Chile (FONASA) would have a minimal budgetary impact.  
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EVALUATION OF THE PHARMACY BUDGET IMPACT OF ALOGLIPTIN PLUS 
PIOGLITAZONE FIXED DOSE COMBINATION IN THE TREATMENT OF TYPE-2 
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1Takeda Pharmaceuticals, Deerfield, IL, USA, 2IMS Health, Alexandria, VA, USA, 3IMS Health, 
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OBJECTIVES: The US burden of type-2 diabetes mellitus (T2DM) remains high 
and available treatment options leave patients with the need for innovative and 
safe treatments. This study assessed the financial consequences of adding 
alogliptin, a novel DPP4i, plus pioglitazone fixed dose combination (FDC) therapy 
to a US managed care health plan formulary. METHODS: An Excel-based model 
was developed to evaluate the therapy costs for patients uncontrolled on any 
pioglitazone- or DPP4i-containing regimen. Baseline costs were estimated for 
branded DPP4i, GLP1s, and FDCs using national market share and average daily 
consumption data from IMS National Prescription Audit (2012); wholesale 
acquisition costs were obtained from Medispan PriceRX (November 2012). 
Alogliptin/pioglitazone FDC adoption was estimated based on one-year expected 
uptake and was priced at parity with the leading DPP4i. Budget impact (BI) was 
calculated as total annual costs and costs per member per month (PMPM). 
Univariate sensitivity analyses were performed. T2DM prevalence and treatment 
data were obtained from published sources. The percentage of T2DM patients 
uncontrolled on pioglitazone and/or DPP4i was estimated from health plan 
claims analysis from January 2011 to September 2011. RESULTS: In a 
hypothetical health plan of 1,000,000 members, the estimated number of adult 
T2DM patients not on insulin and uncontrolled on any pioglitazone or DPP4i-
containing regimen was 13,779. Assuming proportional adoption of 
alogliptin/pioglitazone from all branded DPP4i agents, GLP-1, and FDCs, total 
annual pharmacy costs was $28,015,900 without alogliptin/pioglitazone and 
$28,024,195 with the new FDC, resulting in a BI of $8,295 ($0.00 PMPM, relative BI 
0.03%). In sensitivity analysis, it was assumed that the new FDC pulls share from 
DPP4i and GLP-1s only, resulting in BI of $12,838 ($0.00 PMPM, relative BI 0.04%). 
CONCLUSIONS: Inclusion of alogliptin/pioglitazone FDC on a formulary provides 
an additional effective treatment option and is budget neutral, having a 
negligible impact on the annual pharmacy budget.  
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REDUCING BUDGET IMPACT TO MEXICAN PUBLIC HEALTH CARE SYSTEM 
WITH THE USAGE OF A NOVEL GLP-1 ANALOGUE FOR UNCONTROLLED T2DM 
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OBJECTIVES: To estimate annual savings in Mexican public health care system 
by the usage of lixisenatide for the treatment of uncontrolled type-2 diabetes 
mellitus patients on basal insulin. METHODS: Two different GLP-1 analogues 
(lixisenatide vs exenatide <on National Formulary>) were evaluated from the 
perspective of public institution. A cost-minimization and budget impact 
analysis were conducted. Clinical efficacy was proved to be similar according to 
reported outcomes on a head-to-head clinical trial which included Mexican 
patients comparing the once-a-day administration of lixisenatide 20μg vs 
exenatide 10μg bid. Clinical response on 364 patients was evaluated; no 
statistical significance difference on reduction for fasting and postprandial 
glucose levels, as well as corporal weight loss, was reported; adverse events 
appeared to be less frequent on lixisenatide group than in exenatide group. 
Direct costs were considered on a decision tree with a temporary horizon of one 
year. No discount rate was included. Sensitivity analysis results on variables 
with highest degree of uncertainty were developed. Budget impact analysis was 
applied to different scenarios varying the estimated number of candidate 
patients to GLP-1 analogue treatment based on recent results reported on 
National Survey of Health and Nutrition 2012 (ENSANUT 2012). RESULTS: 
Estimated annual savings account for 279,000 USD. Budget impact reduction was 
established in 0.0008% for national public expenses in health and 0.0099% for 
therapeutic goods expenses in main public health institution in Mexico. 
Sensitivity analysis, showed robustness with base case. Market share scenarios, 
showed that increasing percentage of penetration (PP) of lixisenatide usage may 
result in lower impact to institutional budget (5.5 million USD for 0% PP to 5.2 
million USD for 100% PP) CONCLUSIONS: Glycemic goal level in type-2 diabetes 
patients can be achieved with the synergy of insulin and lixisenatide with a 
corporal weight reduction and cost savings compared to exenatide usage.  
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VALUE ASSOCIATED WITH PHARMACY AND MEDICAL BENEFIT INTEGRATION 
IN A COMMERCIALLY INSURED DIABETIC POPULATION  
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OBJECTIVES: To quantify the impact on medical costs of having an integrated 
medical and pharmacy benefit in the Diabetes Mellitus (DM) population. 
METHODS: Patients who had at least two diabetes ICD-9 codes or two diabetes 
medications refills between January 1, 2006 and December 31, 2006 were 
included. Patients with a diabetes diagnosis or diabetes medications within one 
year before the index date were excluded to ensure a treatment-naïve DM 
population. Only patients continuously enrolled from January 1, 2006 to 
December 31, 2011 were included in this retrospective cohort study. The Gemod 
model with Gamma distribution was utilized to adjust for the baseline disease 
comorbidity, age, gender, and account type differences. A total of 2090 patients 
met the eligibility criteria: 1087 in the integrated group (Members using an 
integrated medical and pharmacy benefit) and 1003 in the non-integrated group 
(Members using medical and pharmacy benefits from separate providers). 
RESULTS: The average unadjusted annual mean medical costs were $7,299 in the 
non-integrated group versus $5,561 in the integrated group (p<0.01). From year 1 
to year 5, the growth of adjusted mean medical costs was 53% in the non-
integrated group compared to 47% in the integrated group. The adjusted mean 
medical costs were higher in the non-integrated group (N=1003) than in the 
integrated group (N=1087) in each of the five years (p<0.01). While treatment 
naïve DM patients tended to have relatively low inpatient and emergency room 
costs, in each year, the integrated groups’ mean inpatient and emergency room 
costs were on average $568 lower when compared to the non-integrated group. 
This observed difference was not statistically significant. CONCLUSIONS: The 
DM patients in the integrated group had lower medical costs and lower inpatient 
and emergency room costs than their non-integrated counterparts. These results 
suggest a value to integrated health benefits; further research is required to 
elucidate the drivers of these observed savings.  
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OBJECTIVES: The prevalence of diabetes in the US and its economic burden 
continue to increase. Improving A1c levels is associated with patient-level cost 
savings. We combined a claims analysis with estimated cost data from published 
literature to predict cost savings at a health plan level when patients achieve 
specific A1c reductions. METHODS: Adult patients with diabetes and continuous 
health plan enrollment in 2011 were selected from the HealthCore Integrated 
Research DatabaseSM, representing a large national health insurer. The 
distribution of A1c levels in this sample was extrapolated to the health plan 
level. Estimated 1-year all-cause patient-level cost savings (medical plus 
pharmacy) associated with reducing A1c from ≥7% to <7% (ADA-recommended), 
as well as from a mean A1c reduction of ≥1%, were taken from published 
literature. Costs were adjusted to 2011 levels. RESULTS: Among all identified 
patients mean age was 60.1 years, 47.5% were female, 96.9% had type 2 diabetes, 
58.6% had ≥1 OAD fill and 22.9% had ≥1 insulin fill. A1c results were available for 
17.0% of patients. Extrapolating the A1c distribution to the health plan level 
(with 700,000 qualifying patients), 323,895 patients (46.3%) had an A1c ≥7% and 
96,556 (13.8%) had an A1c>9%. Mean cost reductions were estimated to be $536 
(≥7% to <7%) and $1,169 (1% A1c reduction) per patient. If 25% of patients 
currently at A1c ≥7% would achieve <7%, the estimated cost savings at the health 
plan level are $43.4m (±10%: $39.1m to $47.8m). Alternatively, evaluating patients 
with poor diabetes control (A1c>9%) only, assuming that 50% of these patients 
experience a mean A1c reduction of ≥1%, the estimated cost savings are $56.4m 
(±10%: $50.8m to $62.1m). CONCLUSIONS: Modest improvements in A1c levels, 
whether evaluated across the population or only in patients with poor control, 
would be associated with substantial cost savings at the health plan level.  
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RELEVANT COMPOSITE ENDPOINT FOR PATIENTS WITH TYPE-2 DIABETES ON 
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OBJECTIVES: To investigate the cost of treatment success (cost of control) in 
patients with type-2 diabetes (T2DM) achieving a composite endpoint of blood 
glucose, weight and hypoglycaemia with liraglutide 1.2mg once-daily as 
compared to other relevant antidiabetic therapies in China. METHODS: To 
measure the ability to obtain control of diabetes, a single composite endpoint 
